Most Read Articles
Rachel Soon, 08 Apr 2020

Guidelines for local pharmacists on what actions to take during the COVID-19 pandemic have been issued by the Malaysian Pharmaceutical Society (MPS).

Elaine Soliven, 20 May 2020
Early treatment with a triple antiviral combination of lopinavir-ritonavir, ribavirin, and interferon beta-1b significantly shortens the duration of virus shedding and reduces symptoms in patients with mild-to-moderate COVID-19 compared with lopinavir-ritonavir only, according to a recent study.
Pearl Toh, 26 Sep 2019
The Singapore Health Sciences Authority (HSA) has recalled eight brands of ranitidine products containing trace amounts of the nitrosamine impurity NDMA*, which is a potential human carcinogen.
Roshini Claire Anthony, 27 May 2020

The use of a vaginal cleansing intervention prior to Caesarean delivery reduced the incidence of surgical site infections (SSIs), according to a study presented at ACOG 2020. However, the addition of intravenous (IV) azithromycin prophylaxis had no added impact on SSI rates. 

Disparity seen between anticoagulation prescription, guidelines

13 May 2019

Prescribing of prophylactic anticoagulation appears to be inconsistent with current practice guidelines, suggests a recent study. However, there appears to be lower thromboembolic events than recorded in previously published literature.

Of the 130 patients included in the study, 92 (70.8 percent) were prescribed lenalidomide and 38 (29.2 percent) pomalidomide. Nearly half of the patients (n=54; 41.5 percent) had a total risk score of 2. Aspirin 81 mg oral tablet was the most common prescription (n=53; 40.8 percent), followed by no anticoagulation (n=30; 23.1 percent).

A total of 27 patients (20.8 percent) were prescribed anticoagulation in accordance with National Comprehensive Cancer Network guidelines. The most common adverse event was incidence of deep venous thromboembolism (n=4; 3.1 percent), followed by major bleeding (n=1; 0.8 percent). There were no reported incidence of pulmonary embolism, myocardial infarction or stroke.

This retrospective study at an ambulatory oncology clinic evaluated overall adherence to guideline recommendations for anticoagulation therapy with lenalidomide and pomalidomide in multiple myeloma patients. The authors utilized chart reviews from the calendar years 2013–2016.

Prescription of appropriate anticoagulation upon initiation of therapy based on a list of predetermined risk factors was the primary endpoint, while secondary endpoints included incidence of deep venous thromboembolism, pulmonary embolism, myocardial infarction, stroke and major bleeding; initial anticoagulant prescribed; and whether or not anticoagulation was prescribed for another disease state.

“Lenalidomide and pomalidomide are two immunomodulatory medications with the potential to improve outcomes for patients with multiple myeloma; however, a black box warning for venous thromboembolism exists,” the authors said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Rachel Soon, 08 Apr 2020

Guidelines for local pharmacists on what actions to take during the COVID-19 pandemic have been issued by the Malaysian Pharmaceutical Society (MPS).

Elaine Soliven, 20 May 2020
Early treatment with a triple antiviral combination of lopinavir-ritonavir, ribavirin, and interferon beta-1b significantly shortens the duration of virus shedding and reduces symptoms in patients with mild-to-moderate COVID-19 compared with lopinavir-ritonavir only, according to a recent study.
Pearl Toh, 26 Sep 2019
The Singapore Health Sciences Authority (HSA) has recalled eight brands of ranitidine products containing trace amounts of the nitrosamine impurity NDMA*, which is a potential human carcinogen.
Roshini Claire Anthony, 27 May 2020

The use of a vaginal cleansing intervention prior to Caesarean delivery reduced the incidence of surgical site infections (SSIs), according to a study presented at ACOG 2020. However, the addition of intravenous (IV) azithromycin prophylaxis had no added impact on SSI rates.